Planul Național De Combatere A Cancerului

Objectives

Romania’s National Plan for Cancer Prevention and Control provides the national framework for 2023–2030, covering prevention, early detection, diagnosis, treatment, palliative care, psycho-oncology, onconutrition, oncofertility, social support and food allowances. It aims to create a standardised, integrated and multidisciplinary patient pathway across levels of care, aligned with the European Beating Cancer Plan and relevant World Health Organization and European Union directions.[1][2][3]

• Strengthen primary prevention by addressing tobacco, alcohol, nutrition, ultraviolet radiation, pollution, human papillomavirus, benzene and radon, while improving health literacy and countering misinformation.[4][5][6]
• Expand organised, population-based screening and earlier diagnosis for priority cancers, including colorectal, breast, cervical, lung, prostate, haematological and rare cancers.[7][8][9][10][11][12][13]
• Improve equitable access to timely, guideline-based diagnosis and treatment through standard diagnostic packages, published patient pathways, regional networks, specialised centres and defined time standards.[14][15][8][9]
• Advance personalised medicine through biomarker, genetic, immunohistochemical and comprehensive genomic testing, health-data infrastructure, artificial intelligence, telemedicine and access to targeted cellular therapies.[16][17][18]
• Improve quality of life by expanding palliative care, psychological counselling, nutritional support, fertility preservation, survivorship services and support for families and carers.[19][20][21][22]
• Reduce cancer mortality and late-stage diagnosis through cancer-specific objectives, although several amendments revise targets where original mortality or staging goals were considered unachievable or lacked baseline data.[23][24][25]
• Strengthen research, innovation and European collaboration, including participation in personalised-medicine, rare-disease, paediatric oncology and cancer-research networks.[26][27][28][29]

Implementation

Implementation is designed as a nationally coordinated, multi-institutional model led principally by the Ministry of Health, with the National Health Insurance House, Ministry of Finance, National Institute of Public Health, professional bodies, universities, providers, patient organisations and other public authorities contributing according to the measure. Services are to be delivered through legally organised providers according to beneficiary needs, supported by regulations, national programmes, specialised networks, reimbursement arrangements and collaboration with European initiatives.[30][31][32][2]

• Coordinate planning, initiation, implementation, monitoring and evaluation through the Ministry of Health, while assigning operational, financing and public-health responsibilities to other institutions where measures require insurance reimbursement, budget-impact analysis, screening delivery or surveillance.[30][32][23]
• Develop national and regional cancer networks, including connections between Romanian cancer centres and European health networks, alongside cross-border exchange of electronic prescriptions and patient summaries.[33]
• Establish structured patient navigation, separate waiting-list arrangements for oncology investigations, family-doctor roles, multidisciplinary tumour boards and referral protocols to reduce delays and improve continuity of care.[34][35]
• Build specialised capacity through accredited integrated treatment centres, regional service networks, pathology and molecular-diagnostic facilities, radiotherapy services, palliative-care beds and paediatric oncology units.[20][36][37][38][39][28]
• Develop information systems through a functional National Cancer Registry and subregistries, electronic health-record improvements, disease-specific registries and stronger linkage of paediatric registry data with administrative, pathology and hospital sources.[40][41][42]
• Finance the Plan primarily through the state budget via the Ministry of Health, with annual funding set at no less than 20% of nationally approved health-programme funds, subject to the stated force-majeure exception for curative cancer treatment.[31]
• Use separate allocations for reimbursed Plan services and investigations, a proposed Health Innovation Fund, National Oncology Programme subprogrammes for testing, and potential contributions from marketing-authorisation holders for personalised-medicine testing.[43][18][36]
• Monitor implementation through selected indicators, including incidence, mortality, stage at diagnosis, survival, screening coverage, patient-pathway time standards, connected hospitals, service uptake and treatment-process performance.[5][7][8][9][11]
• Apply accreditation, quality assurance, benchmarking, guideline review and registry-based data collection, while recognising that the extracts do not set out a single comprehensive reporting schedule, audit framework or accountability system for all Plan measures.[35][20][44][42]

Monitoring & Evaluation

Monitoring arrangements combine national outcome targets, service-process measures, registries, quality assurance, accreditation and assigned institutional responsibilities. The Ministry of Health is responsible for monitoring and evaluating cancer-control measures, while the National Health Insurance House has an operational role in uniform application of measures.[30][32]However, a single document-wide reporting cycle, evaluation methodology, audit system and accountability framework are not specified.[1][30][45]

• Monitor prevention through cancer incidence by site, diagnosed cases, cancer-specific mortality, risk-factor measures, prevention expenditure, numbers of smokers and people consuming alcohol, and awareness-activity outputs.[5][6][16]
• Use tobacco-control monitoring based on European Commission Eurobarometer data and implementation of European Union tobacco-product legislation; reported smoking prevalence is 30% in Romania compared with 23% in the European Union.[26][3]
• Track the implementation of network development through the number of national and European hospitals connected to cancer-care networks.[33]
• Strengthen surveillance through a functional National Cancer Registry with site-specific subregistries, defined mandatory and optional data variables, and legal mechanisms to enforce reporting obligations.[40]
• Apply accreditation, pathway and timeliness standards, including a 30-day diagnostic period and 60 days from suspicion to treatment initiation for the oncology pathway, where specified.[14]
• Assess guideline quality against European and international standards, publish guidelines, review tumour-board activity and implementation of decisions annually, and use tumour boards as an accreditation criterion for relevant providers.[35][46]
• Measure disease-specific outcomes, including mortality reduction, late-stage diagnosis, survival, screening coverage, follow-up investigations and treatment performance. Targets vary across cancer types, including a 15% mortality reduction for colorectal, breast and cervical cancers, 3.5% annual reductions for bronchopulmonary and rare cancers, and a 10% annual reduction for prostate cancer.[15][8][9][10][11][13]
• Use coordinated screening databases, cancer registries and quality assurance to support population screening, including colorectal screening.[44][47][48]
• Monitor personalised medicine and digital-health readiness using the European Personalised Health Index or European Personalised Medicine Index; Romania is reported as ranked 32nd among 34 assessed countries.[17][49][19]
• Improve paediatric cancer surveillance through the National Registry of Childhood Cancers, increased data linkage and more complete case ascertainment; the registry has covered the national paediatric oncology and haematology network since 2010.[28][42]
• Address registry gaps in haematological malignancies, where incomplete or absent national registries constrain reliable incidence, mortality and outcome assessment.[41][50][51]
• Monitor palliative-care provision through benchmarking and accreditation requirements, including a palliative-care section or department in specified oncology hospitals.[20]

Costing & Financing

Financing is principally assigned to the Ministry of Health from the state budget, with annual funding for the National Plan set at no less than 20% of nationally approved health-programme funds, subject to an exception for force majeure requiring additional sums exclusively for curative cancer treatment.[31]Funding for plan services and investigations is separate from social health insurance and other national curative or preventive programmes.[43]The extracts nevertheless provide no consolidated implementation budget, quantified funding gap, costing methodology or economic assumptions for the full plan.[1][52][30][45]

• Establish and finance a Health Innovation Fund through the state budget, with a proposed four-year budget-setting period and discounted reimbursement arrangements for innovative oncology medicines.[43][53]
• Mobilise financing through the National Oncology Programme for genetic, immunohistochemical, biomarker and comprehensive genomic testing, including proposed contributions from pharmaceutical marketing-authorisation holders where health-insurance resources are limited.[18][36][54][55][56]
• Coordinate resource planning with the National Recovery and Resilience Plan, the Health Operational Programme 2021–2027 and relevant European Union programming frameworks.[23][57][58][59][25]
• Fund priority capacity investments in personalised medicine, digital infrastructure, telemedicine, artificial intelligence, biomarker testing, clinical and manufacturing centres for cellular therapies, and national research and innovation structures, although no quantified national allocations are supplied.[16][60][17][49][27]
• Provide specified supplementary per-patient financing for accredited integrated treatment centres and minimally invasive surgery for colorectal, cervical, bronchopulmonary and prostate cancers.[61][62][38][63]
• Expand palliative-care resources through at least 2,000 public-hospital beds created by the Ministry of Health and financing for up to 4,000 beds by the National Health Insurance House.[20]
• Maintain separate financial planning for colorectal screening and colorectal cancer management, and apply cost-benefit considerations when prioritising population interventions.[44][47]
• Recognise substantial cost pressures associated with innovative medicines, advanced surgery, new structures, workforce training, information systems and high-cost services; the extracts repeatedly require budget-impact analysis but generally do not quantify the required allocations.[64][57][65][66][67][68]
• Identify external financing opportunities through Horizon Europe, the European Cancer Plan, European research partnerships and non-governmental support for the National Registry of Childhood Cancers.[26][69][39][42]